ArticleAmerican journal of translational research2026
Clinical significance of SNRPD1 expression in predicting post-transplant recurrence of hepatocellular carcinoma.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze SNRPD1 expression in hepatocellular carcinoma (HCC) and investigate its impact on post-liver transplantation recurrence and prognosis.
methodsDifferentially expressed genes were identified from the TCGA-LIHC cohort using R-based bioinformatics tools. Kaplan-Meier survival analysis, ROC curves, nomograms, and Cox regression models assessed the diagnostic and prognostic value of SNRPD1 in HCC. Immunohistochemistry was performed to detect SNRPD1 protein expression in 102 paired HCC and adjacent non-tumor tissues, with correlation analysis of clinicopathological parameters and follow-up data.
resultsSNRPD1 expression was significantly higher in HCC than in adjacent tissues (89.2% vs. 15.7%, P < 0.001) and positively correlated with microvascular invasion (MVI) and microvascular density (MVD) (P < 0.05; r = 0.26). Multivariate Cox regression confirmed high SNRPD1 expression as an independent risk factor for poor overall survival (hazard ratio (HR) = 0.679, P < 0.001) and progression-free survival (HR = 2.08, P = 0.025) in transplant recipients. The diagnostic AUC was 0.86. High SNRPD1 expression was associated with significantly shorter median overall survival (OS, 45 vs. 88 months) and progression-free survival (PFS, 46 vs. 75 months) (both P < 0.01).
conclusionSNRPD1 is highly expressed in HCC and correlates with MVI and MVD. High SNRPD1 expression independently predicts poorer post-transplant OS and PFS, suggesting it as a promising prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.